Management of rheumatologic immune-related adverse events (irAEs), inflammatory conditions triggered by immune checkpoint inhibitor (ICI) cancer therapy Abstr OP0358 @RheumNow #EULAR2026 https://t.co/hnU7L7RnU8

• https://x.com/synovialjoints/status/2062818769081192639/photo/1

Many drugs in the pipeline for #Systemic_Sclerosis In particular, stay tuned for: 🔺Nerandomilast (PDE4i) in ILD 🔺CAR T cells (obviously): big RCT trials planned 🔺Bispecific T cell engagers: Teclistamab #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/I7HQtfwuW0

• https://x.com/Nellziade/status/2062817676192362886/photo/1
• https://x.com/Nellziade/status/2062817676192362886/photo/1

#OP0350 UK Biobank analysis found widespread white matter microstructural abnormalities on diffusion MRI in RA, esp in fronto-subcortical & transcallosal pathways, despite no cortical volume/thickness differences on T1 MRI. #EULAR2026 @RheumNow

103 patients with ICI-induced inflammatory arthritis. 37.9% died during follow-up. Maximum prednisone dose above 20mg to treat rheumatologic immune-related adverse events was associated with significantly worse overall survival HR 2.35 (95% CI 1.18–4.69, p=0.015). Cumulative https://t.co/vAmIAH7B64

• https://x.com/synovialjoints/status/2062814501867565297/photo/1

How many patients from real life fulfill the inclusion criteria of clinical trials? Not so many ⬇️ #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/U6vlzOYS4X

• https://x.com/Nellziade/status/2062814200024404354/photo/1

#OP0349 Higher pericoronary fat attenuation (PCATa) in RA vs controls, with PCATa assoc with coronary plaque burden only in RA. Suggests coronary inflammation may precede overt plaque changes; supports PCATa as potential CV inflammation biomarker in RA. #EULAR2026 @RheumNow

#OP0348 CT-based analysis in RA showed increased subcutaneous and intermuscular fat plus reduced muscle quality versus non-RA comparators, despite similar BMI-adjusted muscle area and visceral fat. Highlights “hidden” adverse body composition changes in RA. #EULAR2026 @RheumNow

Optical spectral transmission (OST) a non-invasive light-based scan of hand joints monitored inflammatory arthritis activity over time in 60 patients, 1,312 joints. OST correlated with DAS28-CRP (r=0.500, p<0.001), swollen joint count (r=0.535, p<0.001), and AUC 0.781 for https://t.co/AHrybe1Rrn

• https://x.com/synovialjoints/status/2062809513091027266/photo/1

#OP0347 In CCP-positive at-risk individuals with MSK symptoms, MRI-detected hand tenosynovitis independently predicted progression to IA (HR 1.21), alongside US positivity (HR 2.77). MRI added little predictive value in patients with negative US findings. #EULAR2026 @RheumNow

#OP0346 In clinically suspect arthralgia, US missed ~3/4 cases of tenosynovitis detected by modified Dixon MRI. Compared to mDixon MRI, US sensitivity was 23%; specificity remained 100%. Potential for fast non-contrast MRI in early RA risk stratification. #EULAR2026 @RheumNow https://t.co/h3FhLEC2je

• https://x.com/DrMiniDey/status/2062805874477859058/photo/1

The RADIAL study integrates point-of-care ultrasound into the diagnostic work-up for suspected inflammatory arthritis. 601 patients, 6 diagnoses, 1 algorithm. Result: NPV above 90% for most diagnoses. The Double Contour sign for gout: OR 52.66. PPV for RA: 0.85. Ultrasound at

#OP0345 Lung US outperformed clinical risk scores for detecting RA-assoc ILD, incl in asymptomatic patients. Compared with HRCT, LUS achieved 95.4% sensitivity & 77.7% specificity. Combining LUS with risk scores incr sensitivity to 100% for ILD detection. #EULAR2026 @RheumNow

Live vaccinations in infants antenatally exposed to bDMARDs ⬇️⬇️ #WIN session @lauraandreoli80 #EULAR2026 @RheumNow https://t.co/84MCwb2fbT

• https://x.com/Nellziade/status/2062802639180435889/photo/1

Dr. Laura Andreoli shares this slide showing the impact of rheumatic disease in reproductive health as described by Dr. MOstensen. These interplay of factors affect patients and should be taken into consideration when managing fertility & pregnancy. @RheumNow #EULAR2026 https://t.co/fB9kuD4kXo

• https://x.com/RHEUMarampa/status/2062801827276476709/photo/1

Double targeted therapy in refractory SpA/PsA. 76 patients, 17 Spanish centres, up to 6 years follow-up. Median 4 prior biologics. Remission achieved in 55.6% during follow-up. 28.6% in remission at final visit. ASDAS improved significantly from 3 months, sustained to 5 https://t.co/g1IPstYYuX

• https://x.com/synovialjoints/status/2062799915672031405/photo/1